Harnessing nanoparticles for immune modulation

Trends in Immunology

Volumn 36, Issue 7, 2015, Pages 419-427

  Getts, Daniel R ^a,b,c   Shea, Lonnie D ^d,e   Miller, Stephen D ^b   King, Nicholas J C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Cour Pharmaceutical Development Company ^*  (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; TOXIN; VACCINE;

AUTOIMMUNE DISEASE; BONE MARROW CELL; HOMEOSTASIS; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATION; MONONUCLEAR PHAGOCYTE; NANOTECHNOLOGY; NONHUMAN; OPSONIZATION; PATHOGENESIS; POLYMERIZATION; REVIEW; VACCINATION; ANIMAL; CHEMISTRY; DEVICES; DRUG DELIVERY SYSTEM; IMMUNOTHERAPY; PARTICLE SIZE; PROCEDURES; SURFACE PROPERTY;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; NANOPARTICLES; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 84937631636     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.05.007     Document Type: Review

References (104)

1. Laroui H., et al. Nanotechnology in diagnostics and therapeutics for gastrointestinal disorders. Dig. Liver Dis. 2013, 45:995-1002.
2. Smith D.M., et al. Applications of nanotechnology for immunology. Nat. Rev. Immunol. 2013, 13:592-605.
3. Preiss M.R., et al. Bionanotechnology: Biological Self-assembly and its Applications 2013, Horizon Scientific Press.
4. Getts D.R., et al. Ly6c+ 'inflammatory monocytes' are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J. Exp. Med. 2008, 205:2319-2337.
5. Maldonado R.A., et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:E156-E165.
6. Getts D.R., et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat. Biotechnol. 2012, 30:1217-1224.
7. Yeste A., et al. Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:11270-11275.
8. Getts D.R., et al. Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci. Transl. Med. 2014, 6:219ra217.
9. Hunter Z., et al. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano 2014, 8:2148-2160.
10. Putney S.D., Burke P.A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 1998, 16:153-157.
11. Whittlesey K.J., Shea L.D. Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface. Exp. Neurol. 2004, 190:1-16.
12. Mellman I. Endocytosis and antigen processing. Semin. Immunol. 1990, 2:229-237.
13. Davidson H.W., et al. Endocytosis, intracellular trafficking, and processing of membrane IgG and monovalent antigen/membrane IgG complexes in B lymphocytes. J. Immunol. 1990, 144:4101-4109.
14. Harding C.V., Unanue E.R. Antigen processing and intracellular Ia. Possible roles of endocytosis and protein synthesis in Ia function. J. Immunol. 1989, 142:12-19.
15. Shang L., et al. Nanoparticle interactions with live cells: quantitative fluorescence microscopy of nanoparticle size effects. Beilstein J. Nanotechnol. 2014, 5:2388-2397.
16. Shang L., et al. Engineered nanoparticles interacting with cells: size matters. J. Nanobiotechnol. 2014, 12:5.
17. Gratton S.E., et al. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11613-11618.
18. Champion J.A., Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4930-4934.
19. Adjei I.M., et al. Nanoparticles: cellular uptake and cytotoxicity. Adv. Exp. Med. Biol. 2014, 811:73-91.
20. Park M.V., et al. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles. Biomaterials 2011, 32:9810-9817.
21. Harush-Frenkel O., et al. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem. Biophys. Res. Commun. 2007, 353:26-32.
22. Fromen C.A., et al. Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:488-493.
23. Bal S.M., et al. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine 2011, 29:1045-1052.
24. Koppolu B., Zaharoff D.A. The effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cells. Biomaterials 2013, 34:2359-2369.
25. Hwang T.L., et al. Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles. Int. J. Nanomed. 2015, 10:371-385.
26. Chiu H.W., et al. Cationic polystyrene nanospheres induce autophagic cell death through the induction of endoplasmic reticulum stress. Nanoscale 2014, 7:736-746.
27. Xia T., et al. Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways. ACS Nano 2008, 2:85-96.
28. Christensen D., et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J. Control. Release 2012, 160:468-476.
29. Munks M.W., et al. Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo. Blood 2010, 116:5191-5199.
30. Richards R.L., et al. Liposome-stabilized oil-in-water emulsions as adjuvants: increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen. Immunol. Cell Biol. 2004, 82:531-538.
31. Nakano Y., et al. Surface-linked liposomal antigen induces IgE-selective unresponsiveness regardless of the lipid components of liposomes. Bioconjug. Chem. 2001, 12:391-395.
32. Uchida T. Surface-linked liposomal antigen induces IgE selective unresponsiveness in a T-cell independent fashion. Curr. Drug Targets Immune Endocr. Metab. Disord. 2003, 3:119-135.
33. Matsuoka T., et al. Allergen immunotherapy and tolerance. Allergol. Int. 2013, 62:403-413.
34. Fleischer C.C., Payne C.K. Nanoparticle-cell interactions: molecular structure of the protein corona and cellular outcomes. Acc. Chem. Res. 2014, 47:2651-2659.
35. Fleischer C.C., Payne C.K. Secondary structure of corona proteins determines the cell surface receptors used by nanoparticles. J. Phys. Chem. B 2014, 118:14017-14026.
36. Fleischer C.C., et al. Cellular binding of anionic nanoparticles is inhibited by serum proteins independent of nanoparticle composition. Biomater. Sci. 2013, 1:975-982.
37. Fleischer C.C., Payne C.K. Nanoparticle surface charge mediates the cellular receptors used by protein-nanoparticle complexes. J. Phys. Chem. B 2012, 116:8901-8907.
38. Walczyk D., et al. What the cell "sees" in bionanoscience. J. Am. Chem. Soc. 2010, 132:5761-5768.
39. King, N. and Getts, D. Cour Pharmaceutical Development Company. Immune-modifying particles for the treatment of inflammation, WO2014160465.
40. Maffre P., et al. Effects of surface functionalization on the adsorption of human serum albumin onto nanoparticles - a fluorescence correlation spectroscopy study. Beilstein J. Nanotechnol. 2014, 5:2036-2047.
41. Moghimi S.M., et al. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
42. McDonnell T., et al. PEGylated drugs in rheumatology - why develop them and do they work?. Rheumatology 2014, 53:391-396.
43. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
44. Hamad I., et al. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010, 4:6629-6638.
45. Chawla R., et al. Polylactide-co-glycolide nanoparticles of antitubercular drugs: formulation, characterization and biodistribution studies. Ther. Deliv. 2014, 5:1247-1259.
46. Yu H., et al. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy. J. Control. Release 2014, 205:89-97.
47. Bryant J., et al. Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. Biomaterials 2014, 35:8887-8894.
48. Alexis F., et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5:505-515.
49. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42:463-478.
50. Xiang S.D., et al. Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers. Methods 2013, 60:232-241.
51. Gray E.E., et al. Subcapsular sinus macrophage fragmentation and CD169+ bleb acquisition by closely associated IL-17-committed innate-like lymphocytes. PLoS ONE 2012, 7:e38258.
52. Backer R., et al. Effective coll-aboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:216-221.
53. Mohanan D., et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J. Control. Release 2010, 147:342-349.
54. Kourtis I.C., et al. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS ONE 2013, 8:e61646.
55. Vinogradov S.V., et al. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliv. Rev. 2002, 54:135-147.
56. Wong J., et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Drug Deliv. Rev. 2008, 60:939-954.
57. Choi H.S., et al. Renal clearance of quantum dots. Nat. Biotechnol. 2007, 25:1165-1170.
58. Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products 2014, FDA, US Department of Health and Human Services.
59. Sharma R., et al. Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities. Biotechnol. Adv. 2014, 33:64-79.
60. Zhao L., et al. Nanoparticle vaccines. Vaccine 2014, 32:327-337.
61. Haddadi A., et al. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. J. Biomed. Mater. Res. A 2008, 84:885-898.
62. Guzman L.A., et al. Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation 1996, 94:1441-1448.
63. Stebbings R., et al. Safety of biologics, lessons learnt from TGN1412. Curr. Opin. Biotechnol. 2009, 20:673-677.
64. D'Elia R.V., et al. Targeting the "cytokine storm" for therapeutic benefit. Clin. Vaccine Immunol. 2013, 20:319-327.
65. Paessler S., Walker D.H. Pathogenesis of the viral hemorrhagic fevers. Annu. Rev. Pathol. 2013, 8:411-440.
66. Honore P.M., et al. Con: dialy- and continuous renal replacement (CRRT) trauma during renal replacement therapy: still under-recognized but on the way to better diagnostic understanding and prevention. Nephrol. Dial. Transplant. 2013, 28:2723-2727. discussion 2727-2728.
67. Honore P.M., et al. Newly designed CRRT membranes for sepsis and SIRS - a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J. 2013, 59:99-106.
68. Cox D.A. Effects of plasma components from naive and West Nile virus-infected mice on cellular uptake of immune modulating microparticles. Australasian Society for Immunology Annual Scientific Meeting 2014 2014.
69. Vago J.P., et al. Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing neutrophil apoptosis. J. Leukoc. Biol. 2012, 92:249-258.
70. D'Acquisto F., et al. Annexin-1 modulates T-cell activation and differentiation. Blood 2007, 109:1095-1102.
71. Ziegler-Heitbrock L. Monocyte subsets in man and other species. Cell. Immunol. 2014, 289:135-139.
72. high monocyte subpopulation transports Listeria monocytogenes into the brain during systemic infection of mice. J. Immunol. 2004, 172:4418-4424.
73. Geissmann F., et al. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
74. Shi C., Pamer E.G. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 2011, 11:762-774.
75. Shi L., et al. Genome-wide analysis of interferon regulatory factor I binding in primary human monocytes. Gene 2011, 487:21-28.
76. Getts D.R. Editorial to special issue: monocytes in homeostasis and disease. Cell. Immunol. 2014, 291:1-2.
77. Getts D.R., et al. Targeted blockade in lethal West Nile virus encephalitis indicates a crucial role for very late antigen (VLA)-4-dependent recruitment of nitric oxide-producing macrophages. J. Neuroinflamm. 2012, 9:246.
78. Majmudar M.D., et al. Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation 2013, 127:2038-2046.
79. Miller S.D., et al. The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J. Exp. Med. 1979, 149:758-773.
80. Lutterotti A., et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a Phase 1 trial in multiple sclerosis. Sci. Transl. Med. 2013, 5:188ra175.
81. Getts D.R., et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J. Immunol. 2011, 187:2405-2417.
82. Chow I.T., et al. Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development. PLoS ONE 2014, 9:e112882.
83. Delong T., et al. Novel autoantigens for diabetogenic CD4 T cells in autoimmune diabetes. Immunol. Res. 2013, 55:167-172.
84. Sollid L.M., et al. Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics 2012, 64:455-460.
85. + T cell response: a comparative study. J. Control. Release 2014, 192:209-218.
86. Bennett G.D., Kay M.M. Homeostatic removal of senescent murine erythrocytes by splenic macrophages. Exp. Hematol. 1981, 9:297-307.
87. Bratosin D., et al. Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review. Biochimie 1998, 80:173-195.
88. Strydom N., Rankin S.M. Regulation of circulating neutrophil numbers under homeostasis and in disease. J. Innate Immun. 2013, 5:304-314.
89. Chao Y., et al. Recognition of dextran-superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains. Bioconjug. Chem. 2012, 23:1003-1009.
90. Getts D.R., et al. Exploiting apoptosis for therapeutic tolerance induction. J. Immunol. 2013, 191:5341-5346.
91. Chen H., et al. Rapamycin-induced long-term allograft survival depends on persistence of alloantigen. J. Immunol. 1994, 152:3107-3118.
92. Birsan T., et al. Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Transplantation 2003, 75:2106-2113.
93. Horibe E.K., et al. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl. Immunol. 2008, 18:307-318.
94. Kishimoto T.K., et al. Tolerogenic synthetic nanoparticles for the prevention of anti-drug antibodies. 3rd International Conference on Immune Tolerance 2014.
95. Quintana F.J., et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20768-20773.
96. Hauben E., et al. Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood 2008, 112:1214-1222.
97. Nguyen N.T., et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:19961-19966.
98. Park J., et al. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol. Pharm. 2011, 8:143-152.
99. Maile R., et al. Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers. J. Immunol. 2001, 167:3708-3714.
100. Serra P., Santamaria P. Nanoparticle-based autoimmune disease therapy. Clin. Immunol. 2015, Published online February 19, 2015. 10.1016/j.clim.2015.02.003.
101. Prasad S., et al. Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J. Autoimmun. 2012, 39:347-353.
102. Smarr C.B., et al. Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases. Crit. Rev. Immunol. 2013, 33:389-414.
103. Smarr C.B., et al. Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy. J. Immunol. 2011, 187:5090-5098.
104. Wang S., et al. Transient B-cell depletion combined with apoptotic donor splenocytes induces xeno-specific T- and B-cell tolerance to islet xenografts. Diabetes 2013, 62:3143-3150.